AstraZeneca Says Capivasertib Phase 3 Trial Met Primary Endpoints
2022年10月26日 - 3:45PM
Dow Jones News
By Kyle Morris
AstraZeneca PLC said Wednesday that Capivasertib plus Faslodex
significantly improved progression-free survival when compared with
Faslodex combined with a placebo in a Phase 3 trial in advanced
hormone receptor-positive breast cancer.
The Anglo-Swedish pharma giant said the trial met both primary
endpoints of improving progression-free survival in the overall
patient population and in a prespecified biomarker subgroup of
patients whose tumors had qualifying alterations.
The trial will continue to assess overall survival as a key
secondary endpoint, it said.
Breast cancer is the most common cancer in the world with an
estimated 2.3 million patients diagnosed in 2020.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
October 26, 2022 02:30 ET (06:30 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
過去 株価チャート
から 3 2024 まで 4 2024
Astrazeneca (LSE:AZN)
過去 株価チャート
から 4 2023 まで 4 2024
